NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction
NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction
复制标题
DOI：
10.1111/j.1743-6109.2007.00529.x
复制
发表时间：
2007-07-01
影响因子：
3.5
通讯作者：
Maggi, Mario
中科院分区：
文献类型：
--
作者：
Corona, Giovanni;Mannucci, Edoardo;Maggi, Mario
介绍。 2 型糖尿病 (T2DM) 和代谢综合征 (MetS) 的特点是胰岛素抵抗，通常与男性性腺功能减退症相关。区分 T2DM 和 MetS 对男性性腺功能减退症的具体影响。方法。对 1,134 名（平均年龄 52.1 +/- 13 岁）患有性功能障碍的男性患者进行了连续系列研究。主要结果指标。与 ANDROTEST 一起研究了几个激素和生化参数，ANDROTEST 是一项经过 12 项验证的结构化访谈，专门用于筛查性功能障碍男性人群中的性腺功能减退症（总睾酮 [TT] < 10.4 nmol/L 或游离睾酮 [FT] < 37 pmol/L）。结果。无论用于定义性腺功能减退症的标准如何，无论是否患有 T2DM 受试者，MetS 均与该疾病的患病率显着升高相关（与未患有 MetS 和 T2DM 的受试者相比，MetS 且患有或不患有 T2DM 的患者的 TT 和 FT 分别为 41% 和 29% vs. 13.2% 和 77.1% 和 58% vs. 40.6%；均 P < 0.0001）。相反，在患有 MetS 的受试者中，T2DM 与较高的性腺功能减退症患病率相关，但在没有 MetS 的受试者中则不然。与没有 MetS 的患者相比，患有 MetS 的患者（无论是否患有 T2DM）也表现出更高的 ANDROTEST 评分。 Logistic 多元回归分析结合了 MetS 的五个组成部分，确定了无论患有或不患有 T2DM 的患者，腰围升高和高甘油三酯血症与性腺功能减退症之间存在显着关联。结论。我们的研究表明，MetS，特别是内脏肥胖（通过腰围增加和高甘油三酯血症评估）与咨询性功能障碍的受试者的性腺功能减退症特别相关。
Introduction. Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) are characterized by insulin resistance and often associated with male hypogonadism.Aim. To discriminate the specific contribution of T2DM and MetS to male hypogonadism.Methods. A consecutive series of 1,134 (mean age 52.1 +/- 13 years) male patients with sexual dysfunction was studied.Main Outcome Measures. Several hormonal and biochemical parameters were studied along with ANDROTEST, a 12-item validated structured interview, specifically designed for the screening of hypogonadism (total testosterone [TT] < 10.4 nmol/L or free testosterone [FT] < 37 pmol/L) in a male population with sexual dysfunction.Results. Irrespective of the criteria used to define hypogonadism, MetS was associated with a significantly higher prevalence of the condition, both in subjects with and without T2DM (41% and 29% vs. 13.2% and 77.1% and 58% vs. 40.6%, respectively, for TT and FT in patients with MetS and with or without T2DM, when compared with subjects without MetS and T2DM; both P < 0.0001). Conversely, T2DM was associated with a higher prevalence of hypogonadism in subjects with MetS but not in those without MetS. Patients with MetS, with or without T2DM, also showed a higher ANDROTEST score when compared with patients without MetS. Logistic multivariate regression analysis, incorporating the five components of MetS, identified a significant association of elevated waist circumference and hypertriglyceridemia with hypogonadism both in patients, with or without T2DM.Conclusions. Our study demonstrated that MetS, and in particular visceral adiposity (as assessed by increased waistline and hypertriglyceridemia), is specifically associated with hypogonadism in subjects consulting for sexual dysfunction.